Advertisement

India tests coronavirus vaccine delivery system with nationwide trial

Click to play video 'Coronavirus: WHO says countries must not be punished ‘for transparently sharing new scientific findings’' Coronavirus: WHO says countries must not be punished ‘for transparently sharing new scientific findings’
WATCH: WHO says countries must not be punished ‘for transparently sharing new scientific findings’ – Dec 28, 2020

India tested its COVID-19 vaccine delivery system with a nationwide trial on Saturday as it prepares to roll out an inoculation program to stem the coronavirus pandemic.

The trial included data entry into an online platform for monitoring vaccine delivery, along with testing of cold storage and transportation arrangements for the vaccine, the health ministry said in a statement.

Read more: As U.S. hits 20 million coronavirus cases, lawmakers call for action on vaccine plan

The massive exercise came a day after a government-appointed panel of experts held a meeting to review the applications of potential vaccine candidates, including front-runner Covishield, developed by Oxford University and U.K.-based drugmaker AstraZeneca.

India’s vaccination drive is expected to start in a few days once the country’s regulator approves a vaccine.

Story continues below advertisement

The government plans to inoculate 300 million people in the first phase of the vaccination program, which will include healthcare and front-line workers, police and military troops, and those with comorbidities who are above the age of 50.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

The government is expected to initially lean on the vaccine produced by Serum Institute of India, the world’s largest vaccine manufacturing company. The company has been contracted by AstraZeneca to make 1 billion doses for developing nations, including India. It has applied to India’s drug regulator for early approval for emergency use in the country. Applications for vaccines made by Pfizer Inc. and Indian manufacturer Bharat Biotech are also being reviewed.

Click to play video 'Vaccine rollout pace criticized as U.S. tops 20 million cases' Vaccine rollout pace criticized as U.S. tops 20 million cases
Vaccine rollout pace criticized as U.S. tops 20 million cases – Jan 1, 2021

Serum Institute of India’s vaccine doesn’t require the ultra-cold storage facilities that some others do. Instead, it can be stored in refrigerators. This makes it a feasible candidate, not just for India but also for other developing nations.

Story continues below advertisement

Indian Health Minister Harsh Vardhan reviewed the preparedness for the vaccination drive at a government hospital in New Delhi on Saturday and urged the public not to pay heed to anti-vaccine rumours. “We will not compromise on any protocol before approving a vaccine,” he told reporters.

Read more: WHO approves Pfizer vaccine for emergency use, paving way for rollout to countries in need

Pooja Moriya, a health worker in the capital who will be one of the first to be inoculated, said hospital staff has had several meetings about the vaccine and how it works. “Our seniors have told us to not be scared at all,” Moriya said.

India has confirmed over 10.3 million coronavirus cases, second in the world to the U.S. More than 149,000 people have died from the virus in India.